Metoprolol Egis (Metoprolol Tartrate)

Metoprolol Tartrate selectively blocks β1‑adrenergic receptors in the heart. By inhibiting the effects of adrenaline and noradrenaline, it slows the heart rate, lowers myocardial contractility, and reduces cardiac output, which together lower blood pressure and oxygen demand.

The appropriate dose of Metoprolol Egis is determined by the prescribing clinician based on the individual’s medical condition, response to therapy, and other medications. Patients should follow the dosage instructions provided by their healthcare professional.

Safety data for Metoprolol Egis in pregnancy and lactation are limited. The drug should only be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant, and this decision must be made by a qualified healthcare provider.

To request Metoprolol Egis, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Metoprolol Egis is a cardio‑selective (β1‑selective) blocker, offering a lower risk of bronchospasm compared with non‑selective agents such as propranolol. Its pharmacokinetic profile provides once‑ or twice‑daily dosing options, making it convenient for many patients while maintaining effective blood pressure and heart‑rate control.

Metoprolol Egis should be stored at temperatures below 25 °C in its original container, protected from moisture and direct sunlight. Keeping the product in a dry, cool place helps maintain its stability and potency throughout its shelf life.

Metoprolol Egis is taken orally, usually with or without food, as directed by a healthcare professional. Tablets should be swallowed whole with a glass of water and not crushed or chewed unless specifically instructed.

Serious risks include severe bradycardia, heart block, marked hypotension, bronchospasm in patients with reactive airway disease, and rare allergic reactions such as anaphylaxis. Patients should seek immediate medical attention if they experience fainting, severe dizziness, difficulty breathing, or signs of an allergic response.

Metoprolol Egis is contraindicated in patients with known hypersensitivity to metoprolol or any component of the formulation, those with severe bradycardia, second‑ or third‑degree atrioventricular block without a pacemaker, and individuals in cardiogenic shock. Clinicians should also exercise caution in patients with uncontrolled asthma or severe chronic obstructive pulmonary disease.